BiotechTube

Cytarabine (Phase 1 only) + Lintuzumab-Ac225 + Furosemide (Phase 1 only) + Spironolactone

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

AML

Conditions

AML

Trial Timeline

Oct 1, 2012 → May 1, 2020

NCT ID
NCT02575963

About Cytarabine (Phase 1 only) + Lintuzumab-Ac225 + Furosemide (Phase 1 only) + Spironolactone

Cytarabine (Phase 1 only) + Lintuzumab-Ac225 + Furosemide (Phase 1 only) + Spironolactone is a phase 1/2 stage product being developed by Actinium Pharmaceuticals for AML. The current trial status is completed. This product is registered under clinical trial identifier NCT02575963. Target conditions include AML.

What happened to similar drugs?

2 of 14 similar drugs in AML were approved

Approved (2) Terminated (1) Active (11)
✅Venetoclax + AzacitidineAbbVieApproved
✅Olutasidenib + CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe SubstratesRigel PharmaceuticalsApproved
🔄Quizartinib + Salvage ChemotherapyDaiichi SankyoPhase 3
🔄gilteritinib + LoDAC (Low Dose Cytarabine) + Azacitidine + MEC (Mitoxantrone, Etoposide, Cytarabine) + FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)Astellas PharmaPhase 3
🔄gilteritinib + azacitidineAstellas PharmaPhase 3
🔄Gilteritinib + Cytarabine + Mitoxantrone + Etoposide + G-CSF + FludarabineAstellas PharmaPhase 3
🔄Venetoclax + Azacitidine + DecitabineAbbViePhase 3

Hype Score Breakdown

Clinical
9
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02575963Phase 1/2Completed

Competing Products

20 competing products in AML

See all competitors
ProductCompanyStageHype Score
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
14
AC220Daiichi SankyoPhase 1
29
Quizartinib + Salvage ChemotherapyDaiichi SankyoPhase 3
40
QuizartinibDaiichi SankyoPhase 1
29
gilteritinibAstellas PharmaPre-clinical
26
gilteritinibAstellas PharmaPre-clinical
26
Gilteritinib + Venetoclax + AzacitidineAstellas PharmaPhase 1/2
36
Gilteritinib + PlaceboAstellas PharmaPhase 2
35
Venetoclax + GilteritinibAstellas PharmaPhase 1
29
GilteritinibAstellas PharmaPhase 1
29
Gilteritinib + Ivosidenib + EnasidenibAstellas PharmaPhase 1
36
gilteritinib + LoDAC (Low Dose Cytarabine) + Azacitidine + MEC (Mitoxantrone, Etoposide, Cytarabine) + FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)Astellas PharmaPhase 3
40
gilteritinib + atezolizumabAstellas PharmaPhase 1/2
32
Gilteritinib + Venetoclax + Azacitidine (AZA) + Local standard of care (SOC)Astellas PharmaPhase 2/3
45
gilteritinib + fludarabine + cytarabine + granulocyte colony-stimulating factor (G-CSF)Astellas PharmaPhase 1/2
24
ASP2215Astellas PharmaPre-clinical
26
ASP7517Astellas PharmaPhase 1/2
32
gilteritinib + azacitidineAstellas PharmaPhase 3
40
Gilteritinib + Cytarabine + Mitoxantrone + Etoposide + G-CSF + FludarabineAstellas PharmaPhase 3
44
decitabine Induction Chemotherapy + Induction ChemotherapyEisaiPhase 2
27